Trial DesignDeveloping mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale
Section snippets
Methods
Details of the trial protocols are published elsewhere.20, 21, 23, 24 All studies were conducted according to the CCTRN guidelines with approval of institutional review boards of each participating institution, and each patient provided written informed consent.
Effect of shipping temperature on cell viability and phenotype
Shipping with refrigerated (4°C) packs maintained both cell number and overall viability at levels similar to control samples stored at 4°C for 24 hours (Figure 4, A). The temperatures of the samples were (1) 8°C for 4°C stored samples; (2) 7°C to 14°C for samples shipped with refrigerated packs; (3) usually <5°C for samples shipped with frozen packs; and (4) 19°C to 22°C for room temperature samples. Specimens shipped with frozen packs showed a significant decrease in viability compared with
Discussion
One of the most valuable assets in the cardiovascular field is the Framingham Heart Study data set from which several important diagnostic and prognostic markers have emerged over the past 60 years.29 Yet, to date, it is not possible to correlate the important prognostic and diagnostic data gathered from Framingham patients with one of the more potent therapies envisioned—stem cell–mediated recovery after myocardial or vascular injury. The heterogeneity of clinical outcomes after cell therapy (
Conclusions
Creation of a Biorepository Core Laboratory for characterization of biologics is feasible in a network. Within the United States, samples can be shipped nationally and physiologically relevant measurements can be made in a timely manner from shipped samples. To maximize the use of these cell samples, they should be shipped at 4°C to avoid freezing, and elapsed time from blood draw to processing should be 24 to 48 hours. Adhering to these established SOPs reduces variability in cell phenotype
Disclosures
Conflict of interest disclosure: The authors declare no conflicts of interest.
Acknowledgements
We thank the CCTRN site principal investigators, the site research coordinators, and the patients. We also wish to thank Paul Champoux at the University of Minnesota for his flow cytometry support and advice.
The authors are solely responsible for the design and conduct of this study, all study analyses, and the drafting and editing of the paper and its final contents.
References (31)
- et al.
Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials
J Am Coll Cardiol
(2007) - et al.
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial
Lancet
(2004) - et al.
Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy
J Am Coll Cardiol
(2010) - et al.
Therapeutic angiogenesis induced by local autologous bone marrow cell implantation
Ann Thorac Surg
(2002) - et al.
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow–derived endothelial cells
Lancet
(2000) - et al.
Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and design for TIME: a phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
Am Heart J
(2009) - et al.
Rationale and design for the intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction trial (FOCUS)
Am Heart J
(2010) - et al.
Multicenter cell processing for cardiovascular regenerative medicine applications—the Cardiovascular Cell Therapy Research Network (CCTRN) experience
Cytotherapy
(2010) - et al.
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals
Blood
(2007) - et al.
Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis
Arch Intern Med
(2007)
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial
Circulation
REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow–derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial
Eur Heart J
Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial
JAMA
Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction
Eur Heart J
Comparison of intracardiac cell transplantation: autologous skeletal myoblasts versus bone marrow cells
Handb Exp Pharmacol
Cited by (0)
This study was supported by research grants from the NIH NHLBI (U01 HL087318-01) and by the Production Assistance for Cellular Therapies (PACT) N01-HB-37164 and HHSN268201000008C. The University of Minnesota flow cytometer, a Masonic Cancer Center shared resource, was supported in part by grant NIH P30 CA77598.
- g
For the Cardiovascular Cell Therapy Research Network (CCTRN).
- h
Denotes Biorepository codirectors.